StockData

Mirum Pharmaceuticals vs Ultragenyx Pharmaceutical

MIRM and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MIRM and RARE compare

Mirum Pharmaceuticals is the larger company, worth 3.6 times as much as Ultragenyx Pharmaceutical ($6.0B against $1.6B).

Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 17.5% for Ultragenyx Pharmaceutical).

Ultragenyx Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of −81.7% compared with −139% at Mirum Pharmaceuticals.

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMIRMRARE
Size and price
Market cap$6.0B$1.6B
Share price$91.95$16.70
Change, 1 year28.7%−49.5%
Change, 5 years586%−78.2%
Beta (5Y)0.612.12
Employees3721,371
StockData Score
Total score59 (better)
Valuation score01 (better)
Growth score3 (better)2
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S9.7×2.3× (better)
FCF yield−3.8% (better)−29.7%
Growth
Revenue growth (TTM)44.0% (better)17.5%
Revenue growth, 5Y average–19.9%
Profitability
Operating margin−135%−73.6% (better)
Net margin−139%−81.7% (better)
FCF margin−37.0% (better)−68.2%
Return on equity−703%–
Financial health
Interest coverage−62.1×–
Current ratio2.86 (better)1.73
Altman Z-score−0.22 (better)−5.26
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions110%108%
Held by insiders9.2%4.0%
Insider net buying, 12 months−$32.8M−$3.8M (better)
Short interest, % of float11.1%25.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.